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Background: Gilbert’s syndrome is an inherited disease characterised by mild unconjugated hyperbilirubinaemia caused by mutations in UGT1A1 gene  which lead to decreased activity of UDP-glucuronosyltransferase 1A1. The most frequent genetic defect is a homozygous TA dinucleotide insertion in the regulatory TATA box in the UGT1A1 gene promoter.
Methods and results: A group of 182 Polish healthy individuals and 256 patients with different types of hereditary haemolytic anaemias were examined for the A(TA)nTAA motif. PCR reaction was performed using sense primer labelled by 6-Fam and capillary electrophoresis was carried out in an ABI 3730 DNA analyzer. 
The frequency of the (TA)7/(TA)7 genotype in the control group was estimated at 18.13%, (TA)6/(TA)7 at 45.05% and (TA)6/(TA)6 at 36.26%. There was a statistically significant difference in the (TA)6/(TA)6 genotype distribution between healthy individuals and patients with glucose-6-phosphate dehydrogenase deficiency (p=0.041). Additionally, uncommon genotypes: (TA)5/(TA)6, (TA)5/(TA)7 and (TA)7/(TA)8 of the promoter polymorphism were discovered. 
Conclusion: Genotyping of the UGT1A1 gene showed distinct distribution of the common A(TA)nTAA polymorphism relative to other European populations. Because of a greater risk of hyperbilirubinaemia due to hereditary haemolytic anaemia, the diagnosis of GS in this group of patients is very important. 


Gilbert’s syndrome (GS) is an inherited disorder characterised by mild unconjugated hyperbilirubinemia in blood. It has been estimated that 3-10% of the general population exhibit GS [1]. Unconjugated hyperbilirubinemia is caused by mutations in the UGT1A1 gene which encodes hepatic UDP-glucuronosyltransferase 1A1 (UGT1A1). Mutations lead to decreased activity of UDP-glucuronosyltransferase 1A1 and lower bilirubin conjugation with UDP-glucuronic acid [2]. GS is a mild disorder and there is no requirement for treatment or long-term medical attention. The main symptom of the disease is increased level of serum unconjugated bilirubin usually diagnosed in routine laboratory tests. 
In Europeans, the most frequent genetic defect in the UGT1A1 gene described to date is a homozygous TA dinucleotide insertion in the regulatory TATA box - (TA)7/(TA)7 in the gene promoter [2, 3]. Healthy individuals have six TA repeats - (TA)6/(TA)6. The mutation leads to decreased activity of UDP-glucuronosyltransferase 1A1 by 30% and lower bilirubin conjugation with UDP-glucuronic acid and then the accumulation of serum bilirubin [4].
Hereditary haemolytic anaemias, such as hereditary spherocythosis, thalassaemias and glucose-6-phosphate-dehydrogenase deficiency are a group of disorders in which one of common symptoms is an increase level of serum bilirubin. The coexistence of Gilbert’s syndrome with haemolytic anaemia intensify hyperbilirubinemia and thus interfere with a exact diagnosis.
Here, we report the prevalence of GS in patients with different types of haemolytic anaemia and in healthy individuals. We also discuss the presence of uncommon genotypes detected in Polish patients and healthy subjects. 

MATERIALS AND METHODS 
	Analysis of the number of repeats in the UGTA1 gene promoter was performed on DNA samples from patients with confirmed hereditary haemolytic anaemia (65 with hereditary spherocytosis, 139 with β-thalassemia and 52 with glucose-6-phosphate dehydrogenase deficiency -G6PD) from the Department of Paediatrics, Haematology and Oncology in Warsaw.  Samples from 182 healthy individuals were collected in the Regional Centre of Blood Donation and Hemotherapy in Warsaw. Informed consent was obtained from all participants. This study was approved by the Ethical Committee of the Medical University of Warsaw, Poland. 
	Genomic DNA was isolated from peripheral blood samples using the MagNA Pure Compact Nucleic Acid Isolation Kit I (Roche, Germany). The promoter region of the UGT1A1 gene was amplified by polymerase chain reaction (PCR) with F primer 5’ AAAGTGAACTCCCTGCTACC 3’ and R primer 5’ TGCTCCTGCCAGAGGTT  3’. The primers were designed basing on the GeneBank UGT1A1 sequence (NG_009254.1). The sense primer was labelled with 6-Fam on the 5’ end and with Tet on the 3’ end. PCR was performed using FastStart Taq DNA Polymerase with ready-to-use PCR Grade PCR Mix (Roche, Germany). Cycling conditions comprised 30 cycles of denaturation at 95º for 30 s, annealing at 52º for 30 s, and extension at 72º for 20 s. Following the PCR reaction samples were analysed in the DNA Sequencing and Oligonucleotide Synthesis Laboratory (Institute of Biochemistry and Biophysics, PAS). Samples were prepared for capillary electrophoresis by adding 1 µl of 5-times diluted PCR product to 5.7 µl of formamide and 0.3 µl of a GeneScan ROX 500 DNA ladder (Applied Biosystems, CA, USA) as an internal standard. The samples were then denatured for 5 min at 95°C and cooled to 4°C. Electrophoresis was performed in an ABI 3730 DNA Analyzer (Applied Biosystems, CA, USA) using a POP-7 polymer (Applied Biosystems, CA, USA). After electrophoresis the runs were analyzed visually using Peak Scanner Software v1.0 (Applied Biosystems, CA, USA). To confirm the obtained results, selected PCR fragments were sequenced directly with BigDye Terminators and appropriate primers using an ABI Prism 377 sequencer (Applied Biosystems, CA, USA). χ2 test was used to estimate allele frequencies in particular groups. Statistical analysis was done using STATISTICA data analysis software, version 9.1 (StatSoft, Inc., 2010, www.statsoft.com). 

RESULTS 
We determined the frequency of promoter polymorphisms of the UGT1A1 gene in 256 patients with hereditary haemolytic anaemia and 182 controls from the Polish population (Table 1). The frequency of the (TA)7/(TA)7 genotype in the control group was 18.13%, the (TA)6/(TA)7 genotype 45.05%, and (TA)6/(TA)6 -36.26%. Differences between all groups of hereditary haemolytic anaemias and healthy individuals were not statistically significant. However, the (TA)7/(TA)7 genotype was more prevalent in patients with spherocythosis (24.62%) and with G6PD deficiency (23.08%) in comparison with healthy individuals and thalassaemia patients. 
Additionally, we observed a statistically significant difference in the (TA)6/(TA)6 genotype distribution between healthy individuals and patients with glucose-6-phosphate dehydrogenase deficiency, where it was found in only 21.15% of patients (p=0.041). 

Table 1 Frequency of the UGT1A1 gene promoter variants in healthy individuals and in different groups of hereditary haemolytic anaemia in Polish population
Patients	Total	Genotype - number of cases (%)
		6/6	6/7	7/7	5/7	5/6	7/8
Healthy individuals	182	66 (36.26)	82 (45.05)	33 (18.13)	1 (0.55)	0	0
Hereditary spherocytosis	65	24 (36.92)	23 (35.38)	16 (24.62)	2 (3.08)	0	0
β-thalassaemia	139	57 (41.00)	55 (39.57)	25 (17.99)	0	1 (0.72)	1 (0.72)
G6PD	52	  11 (21.15)*	29( 55.77)	12 (23.08)	0	0	0
Total (%)	438	158 (36.0)	189 (43.15)	86 (19.64)	3 (0.68)	1 (0.23)	1 (0.23)
*p<0.05

Extremely rare variants ((TA)5/(TA)6, (TA)5/(TA)7, (TA)7/(TA)8) of the promoter repeat were identified in Polish individuals (Figure 1). The (TA)5/(TA)6 and the (TA)7/(TA)8 genotypes was found only in the β-thalassaemia group but the (TA)5/(TA)7 genotype was found in the hereditary spherocytosis group and in the control group. These rare genotypes were not detected in the group of G6PD-deficient patients. 

DISCUSSION
In this study we present the distribution of the most common TATA box genotypes in 438 Polish individuals. No similar data for Poland is available. The average frequency of the (TA)7/(TA)7  genotype, responsible for a decreased the expression of the UGT1A1 gene, was 19.64%. Several previous studies have reported the prevalence of the (TA)7/(TA)7 variant in European population of 6-10% [1, 4-8], significantly less than the result obtained in our study (Table 2). In contrast with European populations high frequency of (TA)7/(TA)7 allele was found  in some area in Africa, like Nigeria [12], Cameroon, Ghana, southern Sudan and in Ethiopia [6]. On the other hand, there was no systematic, population-based studies on (TA)7 promoter sequence of UGT1A1 gene. Therefore, the discrepancy between our results and some published data may be due to differences between populations/ethnic groups or it may depend on the number of patients involved in the study. 

 Table 2 Frequency of the UGT1A1 gene promoter variants in different European populations. ns - the A(TA)5TAA and A(TA)8TAA motifs were not studied/data of the A(TA)5TAA and A(TA)8TAA motifs not showed
Population	Total	Genotype - number of cases (%)
		6/6	6/7	7/7	5/7	5/6	7/8
Polish	182	66 (36.26)	82 (45.05)	33 (18.13)	1 (0.55)	0	0
Slovenian [1]	236	90 (38.10)	113 (47.90)	32 (13.6)	0	0	1 (0.40)
Greek [4]	37	18 (48.65)	12 (32.43)	7 (18.92)	ns	ns	ns
Swedish [8]	248	112 (45.16)	112 (45.6)	24 (9.68)	ns	ns	ns
Sardinian [9]	70	  39 (55.71)	24(34.29)	7 (10.00)	ns	ns	ns
Scottish [10]	77	40 (31.00)	38 (37.00)	12 (9.00)	ns	ns	ns
Portuguese [11]	75	40 (53.33)	29 (38.67)	5 (6.67)	1 (1.33)	0	0

It has been reported that patients with hereditary spherocythosis or thalassemia minor and co-inherited GS have a greater risk of developing gallstones [5, 7]. The knowledge of the possible coexistence of Gilbert’s syndrome and hereditary haemolytic anaemia would be crucial for an accurate diagnosis of the reason of an increased level of unconjugated bilirubin. Kaplan et al. [13] and Galanello et al. [10] have shown that there was no statistically significant difference in the frequency of (TA)7/(TA)7 among G6PD deficient patients and normal subjects. In our study, the distribution of the three common genotypes was similar in the control group and in the haemolytic anaemia groups. However, the occurrence of the normal (TA)6/(TA)6 genotype  was statistically significant lower in G6PD-deficient patients than in healthy individuals and the number of G6PD-deficient patients with the (TA)7/(TA)7 genotype was higher in this group (statistically insignificant). This finding is important, because promoter variant has been shown to be responsible for hyperbilirubinemia during acute hemolytic anemia in G6PD-deficient patients [14].
In the present study we also discovered rarely observed A(TA)nTAA variants in the promoter region of the UGT1A1 gene. In an African population other variants of the TATA box have been identified: A(TA)5TAA and A(TA)8TAA [15]. The A(TA)5TAA motif does not affect transcriptional activity of the UGT1A1 gene, but patients with the A(TA)8TAA motif, similarly to those with the A(TA)7TAA motif, develop Gilbert’s syndrome [16]. (TA)5/(TA)6 causes a mildly elevated total serum bilirubin, (TA)5/(TA)7 prolonged neonatal jaundice, but (TA)7/(TA)8 genotype has a non-fasting total serum bilirubin that is even slightly higher than in most GS patients [10]. In fact, the (TA)7/(TA)7 variant is mostly observed in Caucasian and African populations whereas in Asians the prevalent mutation is G71R due to a change from G to A in nucleotide 211 in exon 1 of UGT1A1 gene [17]. 
Recently, several rare variants of the UGT1A1 gene promoter have been reported in Caucasians: a (TA)7/(TA)8 variant in an Italian girl [18], (TA)6/(TA)8 in a Greek boy [19], (TA)7/(TA)8 in two girls and (TA)5/(TA)7 in one subject in Portugal [11], and two subjects with (TA)7/(TA)8 and one with (TA)6/(TA)8 variant in Croatia [20]. Our investigation support the suggestion of Iolascon et al.[18] that the A(TA)8TAA motif in the UGT1A1 gene promoter is probably due to spontaneous mutation, because (TA)n repeats are particularly unstable and may be lengthened or shortened by a variety of mechanisms [18]. 
In conclusion, the genotyping of the UGT1A1 gene was carried out in the Polish population for the first time and the results showed a distribution of the common A(TA)nTAA variants slightly different than in other European populations. The present results could be relevant for Northern Europe as the earlier data were obtained mainly in the Mediterranean area. Additionally, we detected promoter variants that are very rare in the Caucasians. Moreover, the (TA)6/(TA)7 and (TA)7/(TA)7 genotypes occurred slightly more frequently in patients with G6PD deficiency. 
It is also noteworthy that such genotyping should be performed in hereditary haemolytic anaemia patients, as Gilbert’s syndrome is a risk factor for developing cholelithiasis. 
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A chromatogram of the capillary electrophoresis of the UGT1A1 gene promoter. The red peak (139) represents an internal standard, the 135 peak (blue) represents the A(TA)5TAA motif, the 137 peak (blue) represents the A(TA)6TAA motif, the 139 peak (blue) the A(TA)7TAA motif, and 141 peak (blue) the A(TA)8TAA motif.



